Obeticholic Acid Under Review for Pre-Cirrhotic Liver Fibrosis Due to NASH
The NDA is supported by two 2 positive interim analyses from the phase 3 REGENERATE trial that included patients with biopsy-proven stage 2 or 3 liver fibrosis due to NASH.
The NDA is supported by two 2 positive interim analyses from the phase 3 REGENERATE trial that included patients with biopsy-proven stage 2 or 3 liver fibrosis due to NASH.
The study authors concluded that ESG is safe for patients with class III obesity and its efficacy was comparable to SG and RNYB.
Patients who underwent colonoscopy after 7 days following their diverticular bleeding episodes demonstrated a significantly higher risk of 30-day mortality.
Pooled analysis of four large-scale trials demonstrated sustained effect on CRC incidence and mortality for 15 years
Beliefs about likely success of antibiotic therapy linked to lower risk for appendectomy, resolution of signs and symptoms by 30 days
The approval was based on data from a phase 1 study that compared the pharmacokinetics, safety, tolerability, and immunogenicity of Hadlima 100mg/mL to 50mg/mL.
Clinical guidelines updated for management of anorectal abscess, fistula-in-ano, and rectovaginal fistula
The approval was based on two phase 3 trials which evaluated Ibsrela in over 1200 adults with IBS-C.
The Company is currently investigating AXA1125 in patients with noncirrhotic NASH with fibrosis in the phase 2b EMMPACT trial.
Preferred approach described for managing ACLF, now emerging as a major cause of mortality in patients with cirrhosis, chronic liver disease